Shawver Laura's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Feb 4, 2025
- Accession no.
- 0001415889-25-002955
- Filed
- Feb 4, 2025
- Trade date
- Feb 3, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $615.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shawver LauraCIK 0001551891 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | MOption exerciseAcquired | +9,064 | $3.15 | +$28,551.6 | 219,410 | Direct | |
| Feb 3, 2025 | Common Stock | MOption exerciseAcquired | +40,936 | $4.85 | +$198,539.6 | 260,346 | Direct | |
| Feb 3, 2025 | Common Stock | SSaleDisposed | −50,000 | $12.31 | −$615,500 | 210,346 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | MOption exerciseDisposed | −9,064 | $0.00 | $0 | 0 | Direct | |
| Feb 3, 2025 | Common Stock | MOption exerciseDisposed | −40,936 | $0.00 | $0 | 124,064 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.